



2 PAVING THE WAY FOR GROWTH




SIPSEN	
AN INNOVATIO	N DRIVEN INTERNATIONAL SPECIALTY PHARMA
A strategic focus on	Three targeted areas : Oncology, Endocrinology and Neuromuscular Disorders
specialist care worldwide	<ul> <li>5 key products accounting for ~ 57% of drug sales</li> <li>Growing at a double digit rate</li> </ul>
A historic presence in primary care	<ul> <li>Focused on gastroenterology, cognitive disorders and cardiovascular diseases</li> <li>A presence focused on selected geographies including France, China and Russia</li> <li>A sound business yielding recurring cashflow and contributing to R&amp;D financing</li> </ul>
A truly differentiating and international R&D capability	<ul> <li>Focused on hormone-dependent diseases, peptide and protein engineering and innovative delivery systems</li> <li>R&amp;D expense in excess of 20% of sales</li> <li>4 centres in Boston, Paris, London and Barcelona</li> </ul>
An integrated player	<ul><li>A fully-fledged peptide manufacturing capability</li><li>Two FDA-approved manufacturing facilities</li></ul>
A recognised strategic partner	<ul> <li>Alliances with international industry leaders in US, Europe and Japan and best-in-class universities around the world</li> <li>Ipsen's business partners include Galderma, Genentech, GTx, Medicis, Roche, Teijin</li> </ul>
4 PAVING THE WAY FOR GROW	лн




		TRATEGY T BUSINESS	O GROW AND	) GLOBALIS	SE ITS
		MISSION	STATEMENT		
To be a worldwid	e best-in-class p		e drugs, addressing unr eutic areas	met medical needs	in its targeted
		STRATEGI			
GROW top-line specialist care by innovative drug t	y providing	<b>GLOBALIZE</b> geographical ex	0	OPTIMIZE r primary care t product life cy management, and focused i	through selected cle partnerships
3 botulinum toxin dossiers under review (US and Europe)	Add a companion product to Dysport <sup>®</sup>	Somatuline <sup>®</sup> US sales ramp-up	Choice of a commercialisation option for Dysport <sup>®</sup> in the US	Adenuric® (febuxostat) partnership	Disclosure by Roche of GLP- 1 (R1583) phase II
	Enrich R&D	OBI-1	Reloxin®	opportunities in Europe	results and phase III





SIPSEN			
SOMATULINE®: A	N IMPROVED PHA	RMACOKINETIC P	ROFILE
Far h market       Far h ark to the	Fight and the second		T
suspension is obtained	Sandostatin LAR®	Somatuline <sup>®</sup> Autogel <sup>®</sup>	1 m
Indications	Acromegaly NET	Acromegaly NET (EU only)	
	1961	NET (EU OITY)	
Administration route	Intramuscular	Subcutaneous	
Administration route Volume injected			
	Intramuscular	Subcutaneous	Comparison Of pre-filled (RHS)














§IPSEN	
WHY CHO US?	OSE IPSEN PHARMA INC. TO LAUNCH DYSPORT® IN THE
A CNS fo	cused company rightly sized to maximize the launch of Dysport®, with 54 staffs
A	team with operational and therapeutic expertise and strong track-record
	Strong managed healthcare experience, especially for injectable drugs
	d targeted market reach, with largely similar prescriber base between Dysport® and rnalis Inc. today covers ~75% of US movement disorder specialists and neurologists
based on s	A sound commercial strategy trong customer relationship and true value-added services provided to physicians
	A lean organization, with no overlap with lpsen's existing structures
Apokyn <sup>®</sup> , th	A well positioned product on the market the only product indicated in the treatment of "off" episodes of Parkinson's disease
Total cor	A reasonable investment sideration of up to \$12.5 million, and investment in Vernalis plc. for \$5.0 million
14 PAVING THE WAY	FOR GROWTH




A STR	ONG PIPELINE TO	D FUEL F	UTURE GROV	νтн	
	NEW CHEMICAL ENTITIES		LIFE CYCL	E MANAGEMENT PROG	RAMMES
3N 83495 STX 64)	Post-menopausal breast cancer	Phase I	Decapeptyl®	Pre-menopausal breast cancer	Phase III
BN 2629 SJG-136)	Advanced metastatic cancers	Phase I completed	Decapeptyl®	6 month SRF (prostate)	Phase III completed
Diflomotecan BN 80915)	Advanced metastatic cancers	Phase II	Somatuline Autogel®	Non functioning neuro endocrine tumors	Phase III
Elomotecan BN 80927)	Advanced metastatic cancers	Phase I	Somatuline Autogel®	Co-administration with Pegvisomant	Phase III
Acapodene®	Treatment of Androgen Deprivation Therapy induced iatrogenic effects	Phase III completed	Somatuline Depot	Neuroendocrine tumors (US)	Phase III
Faspoglutide	Type 2 diabetes	Phase III	Dysport®	Cervical Dystonia	Under regulator review in the US
R1583)	Type 2 diabetes	T Hase III	Botulinum toxin A	Aesthetic medicine	Under regulatory review in the EU
Dopastatin	Acromegaly /Neuro endocrine tumors	Phase I	Reloxin®	Aesthetic medicine	Under regulator review in the U
OBI-1	Haemostasis	Phase II completed	Tanakan®	Mild cognitive impairment related to age	Phase III










Specialty care sales growth
+13.4%
Fully diluted EPS growth
+42.1%






















SG&	SEN A EXPENSES EVOLUTION					
Other sales & marketing expenses	<ul> <li>Efficient containment of actionable Sales &amp; Marketing expenses reflecting productivity improvements</li> <li>Seasonality of Sales &amp; Marketing costs</li> <li>Strong increase in royalties paid to third</li> </ul>	u euros	199.6 39.8	+ 3.6%	206.8 40.8	G&A
	parties partly offset by lower taxes on sales (notably in Spain)	In million euros	135.5 6.4	(+ 3.7%) <b>•</b>	6.1	Other sales & marketing expenses
General & Administrative expenses	<ul> <li>Efficient cost containment</li> </ul>	r	17.9 H1 2007	} <del>+ 5.2%</del> {	19.4 H1 2008	and royalties paid
	Efficient cost containment ar drive SG&A growth be				its	
28 FIR	ST HALF 2008 RESULTS					











SIPSEN CASH FLOW GENERATION			
(In million of euros)	30 June 07	30 June 08	Comments
Cash Flow before change in working capital	112.6	141.3	Increase of receivables (-€36.8m)
(Increase) / Decrease in working capital	(65.3)	(17.1)	Increase of tax payables (+€24,4n
Net cash flow generated by operating activities	47.3	124.1	vs significant decrease in H1 200
Investment in intangible assets and property. plant & equipment	(30.0)	(38.4)	Capex required to maintain
Deposits and other financial investments	(4.3)	-	industrial facilities (-€26.2m)
Others	(12.1)	6.0	Intangible assets investment (-€8
Net cash flow used in investing activities	(46.4)	(32.4)	<ul> <li>Revenues from Ginkor divestment</li> </ul>
Net change in borrowings	2.4	(4.6)	(+€13.8m)
Dividends paid	(50.4)	(55.1)	<ul> <li>Change in working capital linked investing activities (-€12,6m)</li> </ul>
Others	(18.7)	(5.2)	
Net cash flow used in financing activities	(66.8)	(64.9)	<ul> <li>Sale of securities held for sale</li> </ul>
Discontinued operations	2.2	(1.0)	
Change in cash and cash equivalent	(63.7)	25.8	<ul> <li>Share buy back program</li> </ul>
Impact of exchange rate fluctuations	-	(3.0)	1
Closing cash & cash equivalents	220.0	263.7	
Closing Net Cash <sup>(1)</sup>	198.4	239.4	
34 FIRST HALF 2008 RESULTS <sup>(1)</sup> Net cash: cash. cash equivale borrowings and other financial lit			


§IPSEN			
TERCICA'S MAIN IMPACTS	ON IPSEN'S H1 2007	ACCOU H1 2008	NTS
(In thousand euros)			
Convertible notes and warrant			Comments
Change in fair value of warrant – Incl. Exchange rate impact Change in fair value of option	(1 058) <i>(89)</i> (609)	(2 360) (491) (4 944)	<ul> <li>Exercice/conversion date (July 22, 2008) taken into account in the</li> </ul>
<ul> <li>Incl. Exchange rate impact</li> </ul>	(59)	(548)	valuation model
Exchange rate impact on notes w/o option	(1 278)	(1971)	<ul> <li>\$/€ exchange rate evolution</li> </ul>
Interests on convertible Notes	634	10 160	<ul> <li>Accelerated recognition due to</li> </ul>
<ul> <li>Incl. Exchange rate impact</li> </ul>	(2)	(43)	early exercice/conversion date
Impact on financial income	(2 309)	885	·
Corresponding income tax impact	21	(42)	<ul> <li>Reduced rate (1.7%)</li> </ul>
Loss from associates	(2 999)	(4 817)	<ul> <li>Share in Tercica loss (~25%)</li> </ul>
Purchase accounting	(463)	(408)	<ul> <li>Net amortization of Increlex<sup>™</sup></li> </ul>
Loss from associates	(3 462)	(5 225)	
Impact on Ipsen consolidated net profit	(5 750)	(4 382)	
35 FIRST HALF 2008 RESULTS			


SIPSEN BALANCE SHEET	EVOLUT	ΓΙΟΝ			
(In million euros)	S		(In million euros)	lities	
	31 Dec 07	30 Jun 08		31 Dec 07	30 Jun 08
Goodwill	189.0	189.0	Equity	799.9	844.1
Property, plants & equipments	221.9	226.6	Minority interests	1.2	1.4
Intangible assets	89.2	92.5	Total equity	801.1	845.5
Other non-current assets	185.3	95.1	Long-term financial debts	20.8	16.3
Total non-current assets	685.4	603.2	Other non-current liabilities	221.0	223.0
Total current assets	636.8	744.6	Short-term debts	9.2	10.4
Incl. cash and cash equivalents	247.1	269.7	Other current liabilities	265.5	249.1
Assets / discontinued operations	0.7	-	Liabilities / discontinued operations	5.3	3.6
Total assets	1,322.9	1,347.9	Total Liabilities	1,322.9	1,347.9
Net Cash (1)	198.4	239.4			
36 FIRST HALF 2008 RESULTS	(1) Net cash: ca	sh, cash equivalents	and securities held for sales minus bank over liabilities plu	drafts, bank borrowing Is or minus derivative	


million euros)	30 June 07	30 June 08
Payments not yet recognised as revenues in H2	8.3	11.2
Payments not yet recognised as revenues in Y+1	17.2	22.4
Payments not yet recognised as revenues in Y+2 and beyond	167.2	183.3
otal Milestones cashed in but not yet recognised as revenues	192.7	216.9











































## Approximately 2,500 type 2 diabetic patients will be randomized into taspoglutide's phase III program

Stud y	Study	Sample size	Background OAD
1	Monotherapy vs. placebo	330	Treatment-naïve
2	Taspoglutide vs. sitagliptin vs. placebo	630	Metformin
3	Taspoglutide vs. insulin glargine	990	Metformin
4	Taspoglutide vs. exenatide	990	Metformin, TZDs, or metformin + TZDs
5	Add-on to sulfonylurea (± metformin) vs. placebo	200	Sulfonylurea (+/- metformin)
6	Add-on to pioglitazone + metformin vs. placebo	330	Pioglitazone + metformin
			ł

